Why the study?
Is B-type natriuretic peptide an effective screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease?
Population
1,961 subjects without clinical cardiovascular disease, comprising 231 patients with rheumatoid arthritis…
Comparison
B-type natriuretic peptide measurement as a… vs BNP screening performance in non-RA subjects
Design
Cross-sectional
Authors
Loading...
BNP specificity for LVDD is lower in RA; leaves open its screening utility and need for RA-specific validation.
Is B-type natriuretic peptide an effective screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease?
BNP is less effective as a screening tool for left ventricular diastolic dysfunction in patients with rheumatoid arthritis compared to the general population due to lower specificity and higher baseline elevation.
Crowson et al. (2011) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: